How Can You Tell If a Peptide Is Real?

Not by looking at it. A vial containing the wrong sequence, half the stated quantity, or mostly bulking agent looks exactly like one that is correct: white, dry and unremarkable. Every property that would separate them is invisible at the scale a human eye works at, which means visual inspection cannot answer this question no matter how carefully it is done.

So the question has to be broken up before it can be answered at all. "Is it real" is really three questions wearing one coat: is the molecule the sequence claimed, how much of that molecule is actually present, and is anything else in there that matters. Those are three different measurements. No single check covers all three, and the checks that are free cover none of them.

Can you tell anything by looking at the vial?

Almost nothing about the contents, and something useful about the handling. Those are different things, and conflating them is where most confident-sounding advice about spotting fakes goes wrong.

What inspection can establish is physical: whether the seal and stopper are intact, whether the contents are genuinely dry, whether there is any discolouration where the material should be white or off-white, and whether the vial has obviously been warm at some point. Those are real signals and they are worth checking, because they speak to whether the material was handled and stored as it should have been between filling and arrival.

What inspection cannot establish is anything about the molecule. The form the solid takes — a firm cake, a thin film, a loose powder, fragments scattered around the base — is a product of the freeze-drying cycle and the amount of dissolved solid, not of correctness. Vials from a single production run routinely differ in appearance, so differences between vials carry very little information.

And the negative result is uninformative in the strongest sense. A vial that looks perfect tells you nothing, because a vial of the wrong peptide dried under the same cycle would look equally perfect. Visual checking can raise a flag. It can never lower one.

What does the documentation actually establish?

That specific tests were run on a specific batch and returned specific results. That is a genuine claim and a narrow one, and almost all the confusion around certificates comes from treating a narrow claim as a broad one.

The tests themselves are well established. Identity is normally confirmed by mass spectrometry, which measures the molecular mass of the material and compares it with the mass calculated from the claimed sequence — the same analytical foundation used across protein and peptide science generally 1. Purity is normally reported as the share of chromatographic peak area attributable to the main component. Some documents add water content, counterion identity, and bacterial endotoxin. Each is a separate measurement with a separate method behind it.

Where documentation stops is in connecting those results to your vial. A certificate describes a batch. It becomes evidence about the material in your hand only if that material demonstrably belongs to that batch, which is a labelling question rather than an analytical one. This is precisely why release testing in regulated manufacturing is defined per batch against an agreed specification, with the batch identity carried on the container 4.

There is a second limit worth knowing about. A purity percentage is not a statement of how much peptide is in the vial. Synthetic peptides are usually isolated as salts, and the counterion left over from purification, together with residual water, can account for a meaningful share of the mass sitting in the bottom of the container 5. Unless a document reports net peptide content as its own line, it has not addressed quantity at all.

Is independent testing the only definitive answer?

Yes. For identity and purity, analysis performed on the material you actually hold, by a laboratory with no stake in the result, is the only thing that settles the question rather than shifting it.

In practice it is less exotic than it sounds. An analytical laboratory receives a sealed vial or a portion of its contents and runs a short panel. Liquid chromatography coupled to mass spectrometry establishes the molecular mass and therefore whether it is consistent with the claimed sequence. Reversed-phase chromatography with ultraviolet detection gives a purity figure. Amino acid analysis or quantitative nuclear magnetic resonance gives net peptide content, which is the number that answers "how much". Where sterility or endotoxin matters, those are separate assays again.

Turnaround is typically days to a few weeks. The cost of a basic identity-and-purity panel is often comparable to the cost of the material itself for a single vial, which is exactly why sensible practice is to test a batch rather than a vial and let the result stand for the rest of that batch. It is also worth knowing that testing consumes the sample: the vial submitted does not come back.

The quality of the answer depends on the laboratory. Accreditation to the international standard for testing laboratories means an external assessment body has examined that laboratory's competence, impartiality and consistency for a defined scope of tests 3. Scope matters as much as accreditation: a laboratory assessed for one method is not thereby assessed for another, so the report should name the methods used.

Independent testing has limits of its own. It describes the vial tested, on the day it was tested. It cannot tell you how the rest of the batch was stored afterwards, and a purity figure carries the same methodological caveats wherever it was generated. What it does provide that documentation cannot is evidence generated by a party with nothing to gain from the outcome.

Why is the batch number the hinge of the whole question?

Because every piece of evidence in this field is attached to a batch, and if the batch on the vial does not match the batch on the paperwork, the paperwork is describing something else. That single link is what turns a document into evidence, and its absence is what turns evidence back into a brochure.

A batch is one synthesis run, purified in one campaign and filled in one session. That matters because the things people want to know are batch properties rather than product properties. The specific set of related impurities present in a synthetic peptide — deletion sequences, truncated chains, oxidised or deamidated variants — arises from the conditions of that particular run, and the profile differs from one campaign to the next even for the same target sequence 2. Two batches under the same catalogue name are chemically similar, not chemically identical.

This is also why regulated manufacturing tests every batch rather than sampling occasionally: a specification is something each batch must be shown to meet on its own 4. The same logic applies at the buying end. Documentation from a previous batch may be entirely truthful and still tell you nothing about the current one.

The chain to look for is short. There should be a batch or lot identifier on the vial. The same identifier should appear on the certificate. If independent testing has been done, the test report should carry it too. Where all three agree, evidence accumulates and one test can reasonably stand for the batch. Where any link is missing, nothing downstream can be evaluated — not because anyone has necessarily done anything wrong, but because there is no way to tell which material the documents describe.

What is a realistic order of checks?

Cheapest and fastest first, stopping as soon as something fails. Each step costs more than the one before it, so there is no reason to reach for analysis before the free checks have been done, and no reason to trust the free checks to do work they cannot do.

1. Confirm there is a batch or lot identifier on the vial, and that it matches the documentation supplied. If it does not, everything after this is unanchored.
2. Read what the documentation actually reports: which tests, by which methods, on which date, and by whom. A number without a method behind it cannot be interpreted or compared.
3. Inspect the container. Seal intact, stopper seated, contents dry, no discolouration, no sign of the vial having been warm or wet in transit.
4. Check that the reported tests cover what your work depends on. If quantity matters, look for net peptide content, not purity. If sterility or endotoxin matters, look for those specifically.
5. Where a claim is load-bearing for the work, send a vial from the batch for independent identity and purity analysis.
6. Record the batch identifier alongside the result, so that the remaining vials from that batch inherit the evidence rather than requiring it again.

Worth being honest about what this sequence delivers. It does not produce certainty, and no realistic process available to a buyer does. What it produces is a chain of evidence that can be inspected, where every link is either present or visibly missing — which is a great deal better than an impression formed by looking at a white solid through glass.

Which brings the original question back in a more answerable form. Verification happens by measurement or it does not happen at all. Everything short of measurement is an assessment of how much confidence the surrounding evidence deserves — worth making, and not the same thing as an answer.

The useful reframing is to stop asking whether material is genuine and start asking which specific claim matters to the work. If the claim is that the molecule is the stated sequence, mass spectrometry answers it. If the claim is that the vial contains the stated mass of peptide, content analysis answers it and purity does not. If the claim is that no problematic impurity is present, that requires a method capable of detecting the impurity in question. Each of these has an answer. "Is it real" does not, because it is not one question.

And the batch number remains the thing to check first, because it costs nothing and it determines whether any other evidence is admissible. A document tied to a batch that matches the vial can be evaluated on its merits. A document tied to nothing cannot be evaluated at all, however impressive it looks.